CAR-T Cell Therapy (Targeted Therapy for Hematological Malignancies)
Advantage:
China leads the world in the number of CAR-T clinical trials. It has achieved breakthrough cure rates in hematological malignancies like leukemia and lymphoma, offering world-class outcomes at a highly competitive cost compared to Western countries.